Overview

• Sweden rare disease drugmaker's Q1 revenue rose 9% at CER

• Adjusted EPS for Q1 was SEK -0.2

• FDA accepted NDA for Emcitate, granted priority review with PDUFA date set for Sept 28, 2026

Outlook

• Company expects FDA decision on Emcitate by September 28, 2026

• Egetis is accelerating U.S. launch preparations for Emcitate ahead of potential approval

• Company aims to optimize pricing and reimbursement and continue Emcitate launch in Europe

Result Drivers

• EUROPEAN LAUNCH - Revenue growth attributed to Emcitate sales in Europe, with Germany and Italy highlighted as key markets

• NAMED PATIENT SALES - Additional revenue generated from named patient sales in Poland and Turkey

Company press release: ID:nMFN145NVv

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Revenue	Miss	SEK 13.40 mln	SEK 21.85 mln (2 Analysts)
Q1 Adjusted EPS		-SEK 0.20

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Egetis Therapeutics AB (publ) is SEK14.00, about 141.8% above its April 28 closing price of SEK5.79

• The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 9 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.